Biological E Secures WHO Phase II Nod for Novel Polio Vaccine Production

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSimar Singh|Published at:
Biological E Secures WHO Phase II Nod for Novel Polio Vaccine Production
Overview

Hyderabad-based Biological E Limited announced a significant achievement Thursday: the World Health Organization granted phase II pre-qualification for its Novel Oral Polio Vaccine type 2 (nOPV2). This approval validates the complete manufacturing chain for nOPV2 at a single, integrated site. The company has already supplied 700 million doses globally to combat circulating poliovirus outbreaks.

Integrated Manufacturing Milestone

Biological E Limited announced a significant regulatory achievement on Thursday, securing World Health Organization (WHO) phase II pre-qualification for its Novel Oral Polio Vaccine type 2 (nOPV2). This milestone validates the entire manufacturing process for the drug substance and drug product at a single, integrated facility in Hyderabad. The pre-qualification expands the company's WHO-qualified manufacturing scope beyond its previous phase I approval in June 2024, which covered drug product manufacturing using externally sourced drug substance. This integrated approach is designed to enhance global supply chain resilience.

Bolstering Global Polio Eradication Efforts

The vaccine maker has already played a crucial role in global health security, manufacturing and supplying 700 million doses of nOPV2 to the global stockpile. These doses have been distributed to multiple countries actively engaged in immunization campaigns to control circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. Mahima Datla, Managing Director of Biological E Limited, emphasized the critical link between response time, vaccine availability, and the ability to halt polio transmission during outbreaks. She highlighted that nOPV2, with its improved genetic stability, has already surpassed a billion doses administered globally, specifically engineered for outbreak control.

Enhanced Supply Chain Responsiveness

"With phase II WHO pre-qualification enabling full end-to-end manufacturing at our facilities, global supply becomes more resilient and more responsive," Datla stated. "That matters because every delay in outbreak response carries real risk for children and communities." The successful development and qualification reflect collaborative efforts, with significant contributions from PT Bio Farma (Indonesia), PATH, and the Gates Foundation, providing essential technical and programmatic support. Biological E's established integrated manufacturing infrastructure, validated processes, and existing export approvals position it strongly to meet evolving global program requirements and support international outbreak control initiatives, underscoring India's growing leadership in innovative global health solutions.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.